Search

Your search keyword '"Tungsiripat, Marisa"' showing total 23 results
Start Over Author "Tungsiripat, Marisa"
23 results on '"Tungsiripat, Marisa"'

6. Contributors

Author

Abdelmalak, Joseph B., primary, Abelson, Abby, additional, Absi, Ahmed, additional, Achkar, Edgar, additional, Adelstein, David J., additional, Adhami, Talal, additional, Adury, Kamal, additional, Advani, Anjali, additional, Al-Ashkar, Feyrouz, additional, AlMahameed, Amjad, additional, Amado, Antoine, additional, Armogida, Sheila, additional, Armstrong, Wendy S., additional, Arroliga, Mercedes E., additional, Arroliga, Alejandro C., additional, Ashton, Kathleen, additional, Askari, Arman, additional, Atanaskova, Natasha, additional, Attaran, Marjan, additional, Aucejo, Federico, additional, Austerman, Joseph, additional, Avery, Robin, additional, Aydin, H. Nail, additional, Barnes, David, additional, Bartholomew, John R., additional, Batur, Pelin, additional, Baz, Rachid, additional, Bergfeld, Wilma, additional, Bhatt, Deepak, additional, Bharadwaj, Swati, additional, Bianchi, Laura K., additional, Boike, Allan, additional, Bolooki, Michael H., additional, Bolwell, Brian, additional, Bott-Silverman, Corinne, additional, Boyle, Andrew, additional, Bradley, Linda, additional, Braun, William E., additional, Braver, Yvonne, additional, Brener, Sorin J., additional, Brethauer, Stacy, additional, Budev, Marie M., additional, Bunyard, Matthew, additional, Burke, Carol, additional, Butt, Saud, additional, Calabrese, Leonard, additional, Camisa, Charles, additional, Caldwell, Darwin L., additional, Carey, John, additional, Carey, William D., additional, Cesario, Karin, additional, Cevasco, Nathaniel, additional, Chapman, Jeffrey T., additional, Chatterjee, Soumya, additional, Chen, Michael C., additional, Cherian, Neil, additional, Chinnappa, Priya, additional, Choure, Anuja, additional, Chung, Jeffrey Y., additional, Collins, Gregory B., additional, Covington, Edward C., additional, Culver, Daniel A., additional, Curtin, Ronan, additional, Davis, Mellar, additional, Deitcher, Steven, additional, Demirjian, Sevag, additional, Dreicer, Robert, additional, Dresing, Thomas J., additional, Dweik, Raed A., additional, Eghtesad, Bijan, additional, Elder, Julie A., additional, Embi, Peter J., additional, Englund, Kristin, additional, Erzurum, Serpil, additional, Factora, Ronan, additional, Fairbanks, Kyrsten, additional, Faith-Fernandez, Esteban, additional, Falcone, Tatiana, additional, Falcone, Tommaso, additional, Falk, Gary W., additional, Fanning, Suzanne R., additional, Fatica, Richard, additional, Fattal, Omar, additional, Faulx, Michael, additional, File, Elizabeth, additional, Fleseriu, Maria, additional, Fouad-Tarazi, Fetnat, additional, Fowler, Adele, additional, Fox, Robert, additional, Franco, Kathleen N., additional, Fraser, Thomas G., additional, Freda, Benjamin J., additional, Freeman, Katherine, additional, Fung, John J., additional, Garcia, Jorge, additional, Gildea, Thomas R., additional, Golish, Joseph A., additional, Gopinath, Anil, additional, Gordon, Steven, additional, Grandinetti, Lisa, additional, Grasso, Adam, additional, Griffin, Brian, additional, Grimm, Richard, additional, Hajj-Ali, Rula A., additional, Hall, Philip, additional, Hamrahian, Amir H., additional, Harrison, Shannon, additional, Hermida, Teresa, additional, Hernández-Rodriguez, José, additional, Heyka, Robert, additional, Hoffman, Gary S., additional, Hobbs, Robert, additional, Hong, Sandra, additional, Hoogwerf, Byron, additional, Hsieh, Fred, additional, Huang, Julie, additional, Husni, M. Elaine, additional, Ioachimescu, Adriana G., additional, Ioachimescu, Octavian C., additional, Isaacson, Harry J., additional, Isada, Carlos M., additional, Issa, Naim, additional, Jaber, Wael A., additional, Jacob, Ron, additional, Jaeger, Fredrick J., additional, Jaeger, Fred, additional, Jin, Xian Wen, additional, Juvelekian, Georges, additional, Kashyap, Sangeeta, additional, Katzan, Irene, additional, Kaur, Gurjit, additional, Kavuru, Mani, additional, Keys, Thomas F., additional, Khalife, Sami, additional, Khalil, Mazen K., additional, Khasnis, Atul, additional, Kim, Esther S.H., additional, Kim, Richard, additional, Kim, Alice, additional, Koelsch, R., additional, Koening, Curry L., additional, Kooken, Ann R., additional, Kothari, Shakuntala, additional, Krasuski, Richard A., additional, Kunkel, Robert, additional, Lakin, Milton, additional, Lang, David M., additional, LaRosa, Steven P., additional, Lascano, Martin E., additional, Lashner, Bret, additional, Leung, Anthony K., additional, Lever, Harry, additional, Lever, David S., additional, Levin, Kerry H., additional, Lichtin, Alan, additional, Lifshitz, Oren H., additional, Lim, Li Ling, additional, Logan, Daniel, additional, Lucas, Jennifer, additional, Magrey, Marina, additional, Maier, Michael, additional, Malone, Donald, additional, Manzon, Judith, additional, Maroo, Anjli, additional, Mathews, Manu, additional, Mawhorter, Steven D., additional, Mayer, Mark, additional, Mayuga, Ken, additional, Mazzone, Peter J., additional, McAllister, Mark S., additional, McCarthy, Kevin, additional, Maksimowicz-McKinnonn, Kathleen, additional, Mehta, Adi, additional, Mehta, Atul C., additional, Mekhail, Tarek, additional, Miller, Charles M., additional, Moffa, Donald, additional, Moheet, Asma, additional, Molloy, Eamonn, additional, Moore, Halle, additional, Morledge, Thomas, additional, Mossad, Sherif B., additional, Muthusamy, Preetha, additional, Muzina, David J., additional, Nair, Dileep, additional, Nally, Joseph, additional, Nasr, Christian, additional, Noeller, Thomas P., additional, Novaro, Gian M., additional, Nurko, Saul, additional, O'Shea, Robert S., additional, Padmanabhan, Ravindran, additional, Paschall, Velma L., additional, Pien, Lily C., additional, Piliang, Melissa, additional, Pimental, Ronnie, additional, Poggio, Emilio D., additional, Potts, Jeannette M., additional, Pozuelo, Leo, additional, Procop, Gary W., additional, Qadeer, Mohammed, additional, Radojicic, Christine, additional, Rafey, Mohammed, additional, Ranes, Justin L., additional, Raymond, Russell, additional, Remzi, Feza, additional, Rice, Thomas, additional, Rodriguez, Cristina, additional, Rowney, Jess, additional, Sabella, Camille, additional, Sabecks, Ronald M., additional, Sachdeva, Mandi, additional, Foldvary-Schaefer, Nancy, additional, Schauer, Philip, additional, Scheetz, Raymond, additional, Schmitt, Steven, additional, Schrieber, Martin, additional, Seballos, Raul J., additional, Schweikert, Robert A., additional, Sekeres, Mikkael A., additional, Shen, Bo, additional, Shields, Jr., Robert W., additional, Shivadas, Anita, additional, Shoemaker, Laura, additional, Shrestha, Nabin K., additional, Shrestha, Rabin K., additional, Silver, Bernard J., additional, Singh, Rishi P., additional, Singh, Vivek, additional, Skugor, Mario, additional, Smith, Stephen, additional, Soffer, Edy, additional, Solaiman, Firas Al, additional, Sood, Apra, additional, Stephany, Brian R., additional, Stevens, Tyler, additional, Stevens, Glen H.J., additional, Stoller, James K., additional, Streem, David, additional, Sweeney, Patrick, additional, Swiencicki, James F., additional, Taege, Alan, additional, Taliercio, Rachel M., additional, Tallman, Thomas, additional, Tavee, Jinny, additional, Tavill, Anthony, additional, Taylor, David, additional, Taylor, James S., additional, Tesar, George E., additional, Thacker, Holly L., additional, Theil, Karl, additional, Thornton, Sharon Longshore, additional, Tomecki, Kenneth J., additional, Tomford, Walton J., additional, Tung, Rebecca, additional, Tungsiripat, Marisa, additional, Vidimos, Allison, additional, Vogel, Nicola M., additional, Wakim-Fleming, Jamile, additional, Boon Wee, Teo, additional, Whinney, Christopher, additional, Wieckowska, Anna, additional, Wiedemann, Herbert P., additional, Wilke, William, additional, Woodhouse, Justin G., additional, Wright, Bridget, additional, Yamani, Mohamad, additional, Zanotti, Kristine, additional, Zein, Claudia O., additional, Zimmerman, Robert, additional, and Zirwas, Matthew J., additional

Published
2010
Full Text
View/download PDF

12. The Rates of Serious Infections in HIV-infected Patients Who Received Tumor Necrosis Factor (TNF)-α Inhibitor Therapy for Concomitant Autoimmune Diseases

Author

Wangsiricharoen, Sintawat, Ligon, Colin, Gedmintas, Lydia, Dehrab, Admad, Tungsiripat, Marisa, Bingham, Clifton, Lozada, Carlos, and Calabrese, Leonard

Subjects
Adult, Male, Biological Products, Time Factors, AIDS-Related Opportunistic Infections, Tumor Necrosis Factor-alpha, Incidence, HIV Infections, Middle Aged, Viral Load, Article, United States, Autoimmune Diseases, Immunocompromised Host, Young Adult, Risk Factors, Humans, Female, Aged
Abstract

To estimate the incidence of serious infections in patients with HIV infection and autoimmune disease who were treated with tumor necrosis factor (TNF) inhibitors, and to compare these rates by stratified viral load levels.Using a unified search strategy, 4 centers identified HIV-infected patients exposed to TNF inhibitors. Patient characteristics and infection data were assessed via chart review in all patients who were ≥18 years old and who received TNF inhibitor therapy after HIV diagnosis, between January 1999 and March 2015.We studied 23 patients with 26 uses of TNF inhibitor therapy (86.7 person-years of followup). Two (8.7%) experienced at least 1 serious infection episode, for an overall incidence rate of 2.55 per 100 patient-years (95% confidence interval [95% CI] 0.28-9.23). The incidence rate per 100 patient-years was 3.28 (95% CI 0.04-18.26) among patients with a viral load500 copies/ml at therapy initiation and 2.09 (0.03-11.65) among patients with a viral load ≤500 copies/ml.This study suggests that the rate of serious infections in patients with HIV infection under active care who have received treatment with TNF inhibitors may be comparable to the rates observed in registry databases.

Published
2017

15. HIV and Metabolic, Body, and Bone Disorders

Author

Ali, Mohammed K., primary, Magee, Matthew J., additional, Dave, Joel A., additional, Ofotokun, Igho, additional, Tungsiripat, Marisa, additional, Jones, Trammell K., additional, Levitt, Naomi S., additional, Rimland, David, additional, and Armstrong, Wendy S., additional

Published
2014
Full Text
View/download PDF

17. Carotid Intima Media Thickness, Inflammatory Markers, and Endothelial Activation Markers in HIV Patients with Lipoatrophy Increased at 48 Weeks Regardless of Use of Rosiglitazone or Placebo

Author

Tungsiripat, Marisa, primary, El-Bejjani, Dalia, additional, Rizk, Nesrine, additional, Dogra, Vikram, additional, O'Riordan, Mary Ann, additional, Ross, Allison C., additional, Hileman, Corrilynn, additional, Storer, Norma, additional, Harrill, Danielle, additional, and McComsey, Grace A., additional

Published
2011
Full Text
View/download PDF

20. Changes in Peripheral Lipoatrophy, Surrogate Markers of Cardiovascular Disease, and Mitochondria after Rosiglitazone in HIV-infected individuals with Lipoatrophy

Author

Tungsiripat, Marisa

Subjects
Medicine, HIV, antiretroviral therapy complications, lipoatrophy
Abstract

Background: Lipoatrophy, subcutaneous fat wasting, is a stigmatizing complication of antiretroviral therapy (ART). Thiazolidenediones are potent PPARγ agonists and expected to reverse lipoatrophy. Methods: We evaluated rosiglitazone’s effect on several facets of lipoatrophy: 1) limb fat, 2) surrogate markers cardiovascular disease, and 3) mechanistic measures. We conducted a 48-week randomized, double-blind placebo-controlled trial of rosiglitazone in HIV-infected subjects with lipoatrophy on thymidine nucleoside reverse transcriptase inhibitors (tNRTI)-sparing regimens. Results: Rosiglitazone significantly (p=0.02) improved peripheral lipoatrophy in the absence of tNRTIs. Carotid intima media thickness (IMT), oxidative, and some inflammatory markers worsened over time in these subjects on stable ART, regardless of the rosiglitazone assignment. Conclusion: In the absence of tNRTIs, rosiglitazone improved peripheral lipoatrophy. Observed limb fat improvement after rosiglitazone was not associated with changes in surrogate markers of cardiovascular disease or mitochondrial indices. Lipoatrophy can in part be overcome by the PPAR-γ pathway independent of mitochondrial toxicity.

Published
2011

21. HIV and metabolic, body, and bone disorders: what we know from low- and middle-income countries.

Author

Ali MK, Magee MJ, Dave JA, Ofotokun I, Tungsiripat M, Jones TK, Levitt NS, Rimland D, and Armstrong WS

Subjects
Bone Diseases diagnosis, Bone Diseases therapy, Developing Countries, HIV-Associated Lipodystrophy Syndrome diagnosis, HIV-Associated Lipodystrophy Syndrome therapy, Humans, Incidence, Metabolic Diseases diagnosis, Metabolic Diseases therapy, Obesity diagnosis, Obesity therapy, Prevalence, Research, Bone Diseases epidemiology, HIV Infections complications, HIV Infections epidemiology, HIV-Associated Lipodystrophy Syndrome epidemiology, Metabolic Diseases epidemiology, Obesity epidemiology
Abstract

Globally, the HIV epidemic is evolving. Life expectancy for HIV-infected individuals has been extended because of more effective and more widely available antiretroviral therapy. As a result, chronic noncommunicable diseases (NCDs) have become important comorbid conditions. In particular, HIV-infected persons are increasingly at risk of developing metabolic (diabetes, dyslipidemias), body composition (lipodystrophy, overweight/obesity) and bone mineral density abnormalities. We have summarized the published epidemiological and clinical literature regarding these HIV-NCD comorbidities in low- and middle-income countries (LMICs). We found important gaps in knowledge. Specifically, there are few studies that use standardized methods and metrics; consequently, prevalence or incidence data are not comparable. There are very little or no data regarding the effectiveness or cost-effectiveness of clinical monitoring or therapeutic interventions for metabolic disorders in HIV-infected individuals. Also, although NCDs continue to grow in the HIV-negative population of most LMICs, there are few data comparing the incidence of NCD comorbidities between HIV-infected and HIV-negative populations. To address these gaps, we describe potential research and capacity development priorities for the future.

Published
2014
Full Text
View/download PDF

22. Discontinuation of antiretroviral therapy postpartum: no evidence for altered viral set point.

Author

Tungsiripat M, Drechsler H, and Aberg JA

Subjects
Adult, Antiretroviral Therapy, Highly Active, Female, HIV Infections drug therapy, HIV Infections immunology, Humans, Patient Dropouts, Pregnancy, Retrospective Studies, Treatment Refusal, Viral Load, Anti-HIV Agents therapeutic use, HIV Infections epidemiology, HIV Infections virology, HIV-1 physiology, Postpartum Period
Published
2007
Full Text
View/download PDF

23. Dyslipidemia in HIV patients.

Author

Tungsiripat M and Aberg JA

Subjects
Dyslipidemias drug therapy, HIV Infections drug therapy, Humans, Hypolipidemic Agents therapeutic use, Anti-Retroviral Agents adverse effects, Dyslipidemias etiology, HIV Infections complications
Abstract

Thanks to antiretroviral therapy, people with human immunodeficiency virus (HIV) infection are living longer, but as they do, non-HIV medical problems become more relevant. In particular, dyslipidemia, an important reversible risk factor for cardiovascular disease, has been linked to HIV infection and its treatment. Although controversy remains as to whether people with HIV infections will develop premature coronary heart disease, it seems prudent to manage dyslipidemia in these patients just as we do in our HIV-negative patients. Interactions between lipid-lowering drugs and antiretroviral drugs require special attention.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results